← Back to Search

Monoclonal Antibodies

Zilovertamab vedotin for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to ~30 months
Awards & highlights

Study Summary

This trial is testing a new drug for six different types of cancer. The objective is to see if it is effective against cancer, and if it is safe.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to ~30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to ~30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
AUC of MMAE
AUC of total antibody
Area under the plasma concentration-time curve (AUC) of zilovertamab vedotin
+11 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Zilovertamab vedotinExperimental Treatment1 Intervention
Participants will receive zilovertamab vedotin at 2.0 mg/kg given intravenously on Day 1 and Day 8 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zilovertamab vedotin
2019
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Lead Sponsor
1 Previous Clinical Trials
91 Total Patients Enrolled
VelosBio Inc.Lead Sponsor
1 Previous Clinical Trials
91 Total Patients Enrolled
Langdon L Miller, MDStudy DirectorVelosBio Inc.
1 Previous Clinical Trials
91 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment opportunities still available for this experiment?

"Yes, according to clinicaltrials.gov, recruitment is ongoing for this medical trial that was initially posted on October 7th 2020 and recently updated November 16th 2022. 210 participants need to be enrolled across 14 different sites."

Answered by AI

What is the scope of participants involved in this clinical research?

"Affirmative. Clinicaltrials.gov displays evidence that this clinical trial is actively seeking participants after it's original posting on October 7th 2020 and its most recent update from November 16th 2022. 210 individuals have to be recruited across 14 different centres for the study to progress further."

Answered by AI

What beneficial results are researchers hoping to gain from this clinical trial?

"This 18 month trial aims to record changes in tumor dimensions, and secondary outcomes like the rate of adverse events, immunogenicity levels in serum concentrations of VLS-101 reactive antibodies, as well as λz values for VLS-101 determined by pre dose and post dose blood samples."

Answered by AI

What is the extent of participation for this study in America?

"14 sites across the US and Canada are collaborating on this trial. This list of medical centres includes Memorial Sloan Kettering Cancer Center (Site 0007) in New york, Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005) in Hollywood, CHUQ Centre Hospitalier universitaire de Quebec ( Site 0015)in Québec and 11 other locations."

Answered by AI

What potential risks should be considered when administering Zilovertamab vedotin?

"After a careful review of the available data, our team at Power has concluded that Zilovertamab vedotin is fairly safe and scored it with a 2. This rating was given due to the lack of clinical efficacy studies but presence of multiple safety trials."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
The University of Texas Health Science Center at San Antonio ( Site 0004)
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2
Recent research and studies
The Cancer JournalJournal
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia
Kipps, Thomas J.. 2021. “Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia”. The Cancer Journal. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ppo.0000000000000536.
The Cancer JournalJournal
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia
Kipps, Thomas J.. 2021. “Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia”. The Cancer Journal. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ppo.0000000000000536.
clinicaltrials.govStudy
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
2020. "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04504916.
~22 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top